This paper investigates two experimental designs which have been used to evaluate the benefit of the early detection of breast cancer. They have some advantages over a classical design (the screening program versus usual medical care) in that subjects in a control group may benefit by participating in the study. We refer to the two experimental designs as the up-front (UFD) and close-out (COD) designs. The UFD consists of offering an initial exam to all participants. Then they can be randomized to a usual care group or a screening group receiving one or more special examinations. If the outcome of the initial examination is included in the analysis, then the study can answer the question of the benefit of an additional screening program after an initial examination. If the analysis excludes all the cases diagnosed at the initial examination, then the analysis evaluates the benefit of a screening program after elimination of the prevalent cases. These prevalent cases are most likely to be affected by length bias sampling and consequently will tend to have less aggressive disease and live longer. As a result, the UFD can answer two scientific questions. The COD consists of randomizing subjects to a usual care group and a screened group. However, the usual care group receives an examination which coincides at the time of the last exam in the study group. In this paper the power of these two designs have been evaluated. In both cases the power is severely reduced compared to the usual control group receiving no special exams. The power is a function of the sensitivity of the exam, the number and spacings of the exams given to the screened group as well as the sample size, disease incidence of the population and the survival distribution. The theoretical results on power are applied to the Canadian National Breast Cancer Study (ages 40-49) which used an UFD and the Stockholm Mammography Breast Cancer Screening Trial which utilized a COD.
INTRODUCTION
There is growing emphasis on being able to detect chronic disease earlier. The reasoning is that detecting a disease in an earlier state, when combined with effective therapy, may result in higher cure rates or longer survival. There are early disease detection programs for many diseases; e.g. tuberculosis, hypertension, diabetes and many cancers. However, early detection of disease may not necessarily result in increased benefit. Benefit primarily depends on having an effective treatment.
c Oxford University Press (2002) This is especially relevant in the earlier detection and treatment of many solid tumors where the disease may have spread (metastasize) outside the primary site into other organs before the disease is diagnosed. However, the spread of the disease may be microscopic in size and may not be able to be detected. As a result, if the primary site is diagnosed in an early stage and treatment is initiated, the treatment may not necessarily lead to increased benefit if there has been earlier spread of the disease. The metastatic disease will eventually be diagnosed at a later time and will ultimately lead to death.
The possibility that early detection of disease may not necessarily result in benefit has motivated the need for well conducted clinical trials which can generate data for evaluating benefit. The most notable example of such trials is breast cancer in which eight randomized trials have been carried out to evaluate the benefits of a mammogram possibly combined with a clinical exam (Frisell et al., 1991 (Frisell et al., , 1997 Miller et al., 1992a,b; Nystrom et al., 1993; Roberts et al., 1990; Shapiro et al., 1982 Shapiro et al., , 1985 Shapiro, 1997; Tabar et al., 1985 . Despite these clinical trials, there is a controversy about the benefits for women under the age of 50. A NIH consensus conference concluded there was not significant evidence to settle the issue. There is general agreement that women over 50 do benefit which is reflected by lower mortality. However, this conclusion is not completely accepted (see Gotzsche and Olsen (2000) and resulting discussion).
Among the problems with these clinical trials is that they have been planned using the ideas of therapeutic trials. The planning has not taken account the special features of early detection trials which do not arise in the therapeutic trials. To our knowledge, as reflected in the published literature, there was no investigation of the role of the number of examinations and the spacing between examinations and its effect on the statistical power of these studies. As a result these trials have been planned sub-optimally leading to much controversy about their conclusions.
A typical early detection randomized trial will have two groups which will be designated as a control and a study group. Individuals in the control group have their usual medical care, whereas individuals in the study group will have one or more special examinations which have the potential to diagnose disease while it is asymptomatic and the individual has no signs or symptoms of the disease. The special features of these early detection trials, which must be considered in the planning stage, are the number of exams in the study group, the spacing of exams and the optimal follow-up time for analysis. One contrast between therapeutic and early detection trials is that long-term follow-up in early detection trials may lead to reduced power. This feature arises because cases diagnosed in the study group, after the last scheduled examination, may either be those which were evaluated as false negatives or cases which did not have disease at the last examination. It is not possible to distinguish between them at time of diagnosis. As a result, all deaths are included in the mortality comparisons and there is an optimal follow-up time for analysis. A long follow-up time leads to an increase in the number of diagnosed cases not present at the last scheduled examination. This dilution will result in reduced power. The reduction in power is not true for therapeutic trials having long follow-up time. A reviewer has pointed out that this reduction in power would not apply to early detection trials with continuous screening. However, due to costs, all early detection trials use a finite number of exams. Another consideration in planning early detection trials is the choice of the target population. In therapeutic trials all eligible subjects have disease, whereas in early detection trials, subjects do not have disease. However, subjects may be incident with disease at a later time. Thus the choice of the target population for the early detection trial is important (Prorok et al., 1990) . A low-risk population may require a very large number of subjects to achieve adequate power.
The work of Hu and Zelen (1997) we laid the groundwork for planning early detection trials when mortality is the end-point. A brief summary of our findings are: the number of exams and spacing between exams is critical in planning as the more exams the greater the power; however with more exams there is need for longer follow-up time; optimal spacing between exams can be found; larger sample size leads to reduced follow-up time; unequal sample sizes between control and study groups can result in a more efficient experimental design with regard to costs: for example, a fixed number of subjects having only one exam results in lower power compared to half the number of subjects receiving two exams.
The 'classical' clinical design, in which there is a control and a study group, is an ideal way of planning early detection trials. However, since entry into a clinical trial requires subject consent, there may be resistance in consenting to enter a study in which there is the possibility of being assigned to a control group which has no benefit to the individual. The purpose of this paper is to investigate two experimental designs for early detection trials for which there is potential benefit even if subjects are assigned to the control group. These two experimental designs are called the 'up-front design (UFD)' and the 'close-out design (COD)'. Both designs have been used in breast cancer early detection trials (Miller et al., 1992a; Frisell et al., 1991 Frisell et al., , 1997 . have commented on some features of the analysis of the COD. The UFD essentially results in every patient receiving an initial early detection exam. The COD is a trial where subjects in the control group receive a special early detection exam which coincides with the timing of the last exam in the study group. Both of these designs raise special issues which affect the resulting power of the design and in some instances may lead to bias. The UFD presents an issue of whether the cases diagnosed by the initial exam, given to all participants, should be included in the final analysis. We show that the choice will answer two different scientific questions. The COD presents similar issues regarding which diagnosed cases should be included in the analysis. The three options are to include: all cases, only cases diagnosed up to and including the last exam, or the same number of cases in the control and study groups. The different options result in different power and possible biases. This paper is organized as follows. The basic model is defined in Section 2; Section 3 investigates the UFD and Section 4 the COD. In Sections 3 and 4 we use examples of the early detection of breast cancer to illustrate the characteristics of these experimental designs compared to a classical design. Section 5 concludes with a discussion. Throughout, we assume that compliance is complete. An appendix contains the mathematical derivations of equations used for calculations. Due to its length, the appendix is not included in the published paper. It may be accessed on the web page of this paper and also on the web site of this journal for the year 2002.
NOTATION AND MODEL FORMULATION
This paper builds on our earlier paper (Hu and Zelen, 1997) . The notation and basic model will be the same. Define t 0 as the time a subject is registered for the trial. The trial consists of randomizing the subjects into either a control group or a study group. Those assigned to the study group have exams at times t 1 < t 2 < · · · < t n with t 0 < t 1 and t n < T . The time metric may refer to age or chronological time.
The ith interval will be denoted by [t i−1 , t i ) for i = 1, 2, . . . , n. The zeroth interval will be denoted by (0, t 0 ) and the (n + 1)th interval will be [t n , T ). If subjects are followed up to time T , the follow-up time will be (T − t 0 ).
The model for the natural history of the disease is to assume a stochastic process consisting of three states which are designated by S 0 , S p and S c . The state S 0 refers to a disease-free state or if an individual has disease it is asymptomatic and cannot be detected by any diagnostic test. The state S p is the preclinical state and is defined by an individual having disease, but it is asymptomatic and may be diagnosed by appropriate diagnostic tests. The state S c refers to the clinical state, in which under usual care, the disease is diagnosed and treated. The natural history of the disease is assumed to be progressive such that
The appendix summarizes the theory which serves as a basis for calculating the cumulative probability of death for both the control and the study groups under a variety of experimental designs. The cumulative probabilities of death are denoted by θ c (T ) and θ s (T ) for the control and study groups respectively where the argument T refers to the chronological follow-up time. Note that the total follow-up time is (T − t 0 ). The large-sample behavior of the proportion of deathsθ i (T ) is assumed to follow a normal distribution with mean θ i (T ) and variance σ 2 i /n when n is the number of subjects assigned to each group and
, the large-sample power of a one-side α-level test is
Although the power is written with the argument T , it also depends on many other quantities which make up θ i (T ). Our analysis of the proposed experimental designs is centered on the calculation of the power function.
We 
UP-FRONT EXPERIMENTAL DESIGN

Description and discussion
The UDF is defined by giving each subject an initial exam at time t 0 . The subjects may be randomized before or after the initial exam to either a control or a study group. The initial exam may be a different exam than those offered in the study group. For example, in the case of breast cancer detection, the study group exams may consist of both a clinical exam and a mammogram whereas the up-front exam may only consist of a clinical exam. There are two options in carrying out the trial and analyses. One could drop all diagnosed cases from the initial examination and only analyse subjects having a negative up-front exam outcome. Alternatively, all individuals may be included in the analysis regardless of the initial exam outcome. These two options are referred to as the 'drop' and 'keep' options.
If the drop option is used, then the scientific question answered by the study is to evaluate the benefits of screening conditional on the prevalent cases being eliminated (prevalent cases are defined as being in the pre-clinical state at t 0 ). The largest effect of length-biased sampling is on the prevalent cases at t 0 . These tend to have longer sojourn times in the pre-clinical state. Hence, if the clinical course of disease is related to the pre-clinical disease course, this group will tend to have longer survival. Alternatively, if all the individuals are randomized to the two groups, regardless of the up-front exam outcome, it will be possible to answer the question about the benefit of additional periodic exams after an initial exam.
There are two ways of implementing the keep option as outlined by Figures 1a and b. Figure 1a represents the keep option if randomization is carried out after the initial exam whereas Figure 1b shows the keep option if the randomization is carried out before the initial examination. Note that if the prevalent cases are dropped in the analysis, the trial is equivalent to Figure 1c equivalence is independent of when the randomization was carried out. In some applications the outcome of the initial exam may not be known for some period of time, but the randomization is carried out at t 0 . Hence the clinical trial would be carried out according to Figure 1b (randomize all subjects after the initial exam).
A classical experimental design consists of a control and a study group and can generate information on the benefit of the screening exam program: i.e. exam program versus usual medical care. However, the UFD, with either the drop or keep option, does not directly generate data which can unambiguously show the benefit of early detection exams. If the major benefit of the early detection exam is with prevalent cases, then a conclusion of no difference with the drop option does not necessarily mean that early detection is without benefit. Similarly, if the keep option results in a conclusion of no difference, this also does not necessarily mean that early detection is without benefit. The interpretation is that the additional exams may be without significant benefit as the greatest benefit may be with the prevalent cases.
A modification of the UFD can be made by adding a third group (control group which consists of usual medical care). Then one can compare the control group with both the group having an up-front exam and the group having both periodic exams plus the up-front exam. These two comparisons can show the benefit of early detection for prevalent cases and for periodic exams respectively. 
UFD versus classical design
In this section we calculate the power of the UFD for the drop and keep options for a design with three exams spaced two years apart. The power is compared with that of the classical experimental design. In order to carry out the calculations we need to assume numerical values for various parameters. The parameter values used in our calculations are summarized in Table 1 . Since screening for breast cancer motivated our investigation, these values represent reasonable values for breast cancer as ascertained from the literature. To simplify the calculations we assume that the transitions to S p and S c are constant and that the sojourn time distributions in S p and S c are exponential. The power is calculated to detect a 25% reduction in mortality (this was achieved at the HIP trial for women age 50 or younger after 12 ys of follow-up). The assumption that the sojourn times in S p are exponential is based on analyses of the HIP study data. Walter and Day (1983) made an empirical study of this trial and found that an exponential distribution best fits the data. Earlier, Zelen and Feinleib (1969) had proved that the necessary and sufficient condition for the sojourn time distribution in S p to be exponential is that the mean age of cases in the study group (first exam) be the same as the mean age of cases in the control group (the mean age of study group cases in the first exam was 53.8 ys versus 53.3 ys for the control group in the HIP study). Table 2 summarizes the power calculations for the drop and keep options as well as for the classical experimental design. The power of the classical experiment design with n = 24 000 subjects in each group is 0.80. This is the maximum power and is attained with a follow-up time of 11-14 ys. However, the power of the UFD reduces to 0.42 and 0.38 with the drop and keep options respectively.
The drop option requires a sample size of n = 70 000 to have 0.80 power whereas the keep option requires a sample size of 82 000 to reach this same power. In general, the drop option tends to have greater power than the keep option. We also point out that to attain the maximum power with the drop and keep options requires slightly longer follow-up times than the classical design. Smaller follow-up times will result in lower power. The calculations summarized in Table 2 are for a three exam program for the study group. In order to determine the effect on power of having different numbers of examinations, we calculated the power when the number of examinations is two and four keeping the sample size for each group as n = 24 000. The results of the calculations are summarized in Table 3 for both the drop and keep options (the three exam program is also included in this table). In general, power increases with the number of exams, but the required follow-up time is lengthened. These numerical calculations are typical of the effect of an UFD.
The Canadian national breast screening studies
There are two early detection randomized clinical trials which are referred to as the 'Canadian National Breast Screening Studies (CNBSS)' (Miller et al., 1992a,b) . One study was for women aged 40-49 at time of entry; the other was targeted at women aged 50-59 at time of entry. The trial on younger women was planned to have an UFD. This trial recruited subjects to a study group to receive annual mammograms and physical exams whereas the control group received usual medical care. However, all subjects entered into the study received an initial physical examination. The first 62% of women in the study group were offered five annual screening exams and the remaining 38% were offered four exams. The study resulted in n = 25 214 (25 216) subjects randomized to the study (control) group. This is the largest randomized trial in the world to evaluate the benefit of mammography for women 40-49 ys of age. The investigators found no statistically significant difference between the groups. In fact the mortality for the study group was slightly larger than that of the control group.
At the time of randomization, the outcome of the initial physical exam was not known. Hence the trial randomized all subjects to a control or study group. Table 4 summarizes the values of the parameters used to calculate the power. The clinical trial was planned to detect a 40% reduction in mortality with a power of 0.80. According to our calculations this reduction is achieved if the median survival of those found on screening is increased from 10 to 40 ys. Of course this is an idealized survival with no other causes of death. We regard this median survival to be a bit unrealistic. To be more realistic we have calculated the power using a mortality reduction which ranges from 25 to 40%. The power calculations are summarized in Table 5 for both the drop and keep options. We note that a 25% reduction in mortality was achieved 25, 30, 35 and 40% reduction in mortality at 9 ys of follow-up from entry is used for the study group (these result in median survival of 18.5, 23, 30 and 40 ys respectively). c Sensitivity and transition probabilities are estimated by Shen and Zelen (1999) . Note that sensitivity for control group refers to physical exam.
at the HIP trial for women aged 40-49 after 12 ys of follow-up (Shapiro, 1997) . With a 25% reduction in mortality, the maximum power with the keep option is 0.64 and requires 10-13 ys of follow-up time. This is in contrast to the drop option which attains a maximum power of 0.83 with 10-12 ys of follow-up time. The investigators analysed the trial using the keep option. The results from our calculation show that power can be significantly enhanced by dropping the prevalent cases diagnosed at the initial exam. It would be worthwhile to re-analyse this trial with the drop option.
CLOSE-OUT EXPERIMENTAL DESIGN
Experimental design and calculation
The COD is defined by offering the control group a single exam which coincides with the timing of the last exam given to the study group. This design was used in a breast cancer early detection trial begun in 1981 in Stockholm. It is called the Stockholm Mammography Breast Screening Trial (Frisell et al., 1991 (Frisell et al., , 1997 . The trial had two exams in the study group and a delayed exam in the control group which was given at approximately the same time as the second exam in the study group. A comparison of control and study groups answers the question of the magnitude of the benefit of a screening program compared to a delayed single exam. It does not provide unambiguous information on the benefit of early detection versus usual care. Of course if the screening program is significantly better than the delayed single exam, by implication, early detection is beneficial. However, a non-significant outcome implies that there is comparable benefit for the two groups or no benefit for both groups.
Under the COD design, data may be analysed in two ways: (i) compare all deaths in each group or (ii) only use deaths for cases diagnosed up to and including the last exam. called the latter analysis a 'limited mortality analysis'. However, the COD design with the 'limited mortality analysis' will yield a biased result unless there is perfect sensitivity, no refusers and both groups have the last exam at the same time. This bias will favor the study group, but will not be present when all deaths are included in the analysis. Table 6 summarizes the power calculations comparing the classical design having a power of 0.80 to the COD in which all participants are included. The sample size is n = 24 000 in each group. The study group has three exams spaced two years apart. The parameter values are the same as those provided in Table 1 . Note that the power is reduced as expected. In order to have a power of 0.80, a sample size of n = 50 000 is required.
We considered an alternative analysis in order to overcome the bias from a 'limited mortality analysis'. Aron and Prorok (1986) defined a 'catch-up time' as the time until the cumulative number of cases in the control and study groups becomes equal. The analysis is restricted to comparisons of mortality for cases diagnosed up to the catch-up time. Quoting Etzioni and Self (1995), ' . . . the rationale behind 'catch-up' time suggestion is that the 'catch-up' cohort should consist of comparable cases in the control and study groups, and this should provide us with 0.86 (11-13) * 0.59 (7-9) * 0.77 (9) 0.88 (14) (14) 0.76 (36-49) * 11 a COD: follow all participants. Maximum power is achieved with 7-9 ys of follow-up. b COD: follow cases to the 'catch-up' time. Analysis is done at 9, 14 and 23+ ys of follow-up. * Maximum power. Numbers in parentheses refer to follow-up years dated from entry. a comparison group that exhibits the same mortality patterns that the number of cases detected by screening would have displayed in the absence of screening.'
Considering the different design issues, Table 7 summarizes the power calculations with sensitivities ranging from 0.80 to 1.00. We note that with very high sensitivities ( 0.98), the last exam time is almost the 'catch-up' time. This means that the 'catch-up' time approximately coincides with the time of the last screen exam. The COD with the 'catch-up' method analysis results in higher power than the classical design with sensitivity of 0.98 or higher.
With the sensitivity of 0.95, the calculation in Table 7 shows that the maximum power for the classical design is 0.83 (control group not offered a screening exam). For the COD design, the power is 0.68 at 9 ys of follow-up including only cases until the 'catch-up' time, whereas including all cases results in a maximum power of 0.56. At 14 ys of follow-up, this power increases to 0.79. In general, the classical design results in higher power than the COD when all cases are included in the analysis. The COD with the 'catch-up' method analysis results in power which exceeds or equals the power of simply following all patients for the same follow-up time. There exists a trade-off between the classical design and the COD with the 'catch-up' method analysis. To reach the same power, the classical design requires shorter follow-up time and includes all cases. However, the COD with the 'catch-up' method analysis requires longer follow-up time but only includes cases diagnosed up to the 'catch-up' time. We also note that with very long follow-up time the 'catch-up' method analysis may have large power.
The Stockholm trial was carried out using a COD in which the analysis only included mortality for cases diagnosed up to and including the last exam in the study group and the single exam in the control group. This trial started in March 1981. Two screening exams were offered to the study participants between March 1981 and October 1985. After 1985 the design of the study was changed and during 1986 the control women were invited to have a mammogram. After December 1986, no more diagnosed cancer cases were considered in the mortality analysis. This design leads to a bias in favor of the study group unless the exam sensitivity is unity. We illustrate the effect of the bias by calculating the significance levels when the survival distribution is unaffected by the early detection of disease and cases are only included in the analysis for those cases diagnosed up to and including the timing of the last exam. The calculations are summarized in Table 9 using the parameter values in Table 8 . The significance level was chosen to be 5%. Values departing from 5% show a bias. In general, the bias becomes larger with more examinations and lower sensitivity. At a sensitivity of unity, the bias disappears. The bias is always in the direction to favor the study group. 
The Stockholm mammography breast cancer screening trial
As mentioned earlier, the Stockholm trial used a COD. The trial was initiated in 1981 with women aged 40-64. The study group consisted of n = 40 318 women invited to screening whereas the control group consisted of 20 000 age-matched randomly selected women. Two screening exams were carried out between 1981 and 1985. On average the first exam was given 28 months from time of registration and the second round of exams averaged 24 months from the first exam. During 1986 the control group was invited for a single exam and the study ended except for follow-up. We calculated the statistical power comparing the mortality of the two groups for women aged 50-59 at time of study entry. The sample size was n = 25 476 for the study group and n = 12 840 for the control group. The parameter values for power calculation are given in Table 10 and the power calculations are in Table 11 . The calculations show how the power changes with follow-up time. (Table 4) c Prevalence and transition probability are estimated from the results for Stockholm trial. d Sensitivity is estimated by Shen and Zelen (1999) . Initially the Stockholm trial was planned using a classic design. However, due to the lower sample size the power is low and becomes lower by 45% when the control group was offered an exam. Even with a median survival for diagnosed cases of 40 ys, the COD results in a low power of 0.45 at its maximum. We also note that the power will be even lower if there is not 100% compliance. In fact in the Stockholm trial, the participation rate was 81 and 80% in the two rounds, and 77% in the screening of the control group.
DISCUSSION
We have derived the power of the UFD and COD when used to evaluate the benefit of a screening program. The power is a function of the examination sensitivity, the number and spacings of the examinations in the screened group as well as the number of subjects, disease incidence and the survival distribution. Both designs offer potential benefit to a usual care (control) group but at the expense of significantly reducing the power and changing the scientific questions which may be answered. We have illustrated our results by carrying out a series of calculations. In our calculations, we have assumed exponential survival distributions, but the theoretical results hold for any survival distribution.
The UFD can answer two scientific questions: (i) the additional benefit of a screening program after an initial examination and (ii) the benefit of a screening program after the prevalent cases have been eliminated. Of course if the sensitivity of the initial exam is less than unity only a sub-set of the prevalent cases would be eliminated. One reason for utilizing this design is to eliminate the prevalent cases who are most effected by length-biased sampling. These cases have less aggressive disease and tend to live longer.
Figures 1a and b describe the UFD with the 'keep' option. However, the key idea for the UFD design is to eliminate the effect of the prevalent cases. As noted earlier, this tends to reduce the effect of length bias, which is most predominant in the first exam. Theoretically the analysis for the UFD design should use the 'drop' option. However, in some applications the outcome of the initial exam may not be known for some period of time, but the randomization needs to be carried out in a timely manner (usually at the time of registration which may be close in time to when the initial exam is carried out).
The COD suffers from a possible bias. This bias arises because the probability of being in the preclinical state at the close-out exam is higher for the control group relative to the study group; i.e. cases in the study group, which potentially could be present at the last exam, may have been diagnosed on earlier exams and hence removed from the population. As a result there is a higher expected number of false negative cases in the control group when given the close-out exam. The bias disappears if the sensitivity is unity (no false negative cases) or all cases are included in the analysis regardless of when they are diagnosed. Aron and Prorok (1986) suggest that cases be included for analysis when they are diagnosed up to the 'catch-up' time. This time point is defined by the number of diagnosed cases in the control and the study group becoming equal. One problem with this suggestion is that if the sensitivity is not high and the incidence of the disease is low, the 'catch-up' time may take a very long time or may never be reached.
The theoretical results have been applied to the Canadian National Breast Screening Study for younger women (ages 40-49) and the Stockholm Mammography Breast Cancer Screening Trial. The Canadian trials both used an UFD and the Stockholm trial utilized a COD. In both cases the power was significantly reduced. The Canadian study retained all initial exam cases in the analysis. If these cases had been dropped, the power could be significantly raised. Our calculations, assuming a 25% mortality reduction, result in a power of 0.64 with the keep option compared to 0.83 with the drop option. It would be worthwhile to re-analyze the results eliminating the prevalent cases.
Our theoretical results enable one to plan early detection trials such that the control group may receive some potential benefit. However, such trials must have considerably larger sample sizes than a classical design in order to have acceptable power. Furthermore, our theoretical results allow such experimental designs to be optimized as a function of the number of exams, spacings of the exams and follow-up time (Hu and Zelen, 1997) . We hope that further trials will take advantage of our theoretical results and plan these expensive and high-impact trials in an optimal way.
